The Supreme Court heard arguments April 27 on whether federal pesticide law blocks state failure-to-warn suits over Roundup, with more than 3,900 federal cases hanging in the balance.
The Supreme Court heard oral arguments April 27 in *Monsanto Co. v. Durnell*, a case that asks whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state tort failure-to-warn claims brought by cancer patients who allege exposure to glyphosate, the active ingredient in Roundup weedkiller [1]. Bayer AG, which acquired Monsanto in 2018, contends that compliance with EPA-approved labeling standards under FIFRA satisfies any duty to warn and forecloses parallel state law obligations [1]. The plaintiffs, led by John Durnell, argue that FIFRA does not displace state remedies and that the federal label is a floor, not a ceiling [1].
The case arrives at the Court after years of sprawling litigation. More than 100,000 plaintiffs have filed suit over the alleged link between glyphosate and non-Hodgkin lymphoma, and more than 3,900 federal cases remain pending [1][2]. In February 2026, Bayer separately agreed to a $7.25 billion class-action settlement to resolve a portion of those claims, a figure that underscores the financial exposure the company faces across the broader docket [2]. *Durnell* reached the Supreme Court as the vehicle for resolving a recurring circuit-level dispute over FIFRA's preemptive scope.
The substantive stakes are significant. FIFRA expressly preempts state requirements "in addition to or different from" federal labeling requirements, but courts have divided on how far that language reaches in the failure-to-warn context [1]. A ruling for Bayer would effectively immunize pesticide manufacturers from state tort liability whenever their labels comply with EPA standards, collapsing the remaining federal Roundup docket and restructuring tort exposure for the entire industry [1][2]. A ruling for the plaintiffs would preserve state court failure-to-warn claims as an independent avenue for injured consumers, leaving Bayer's litigation exposure largely intact [1].
A decision is expected before the Court's term ends in late June 2026. If the Court rules for Bayer, plaintiffs with pending failure-to-warn claims in federal multidistrict proceedings would face dismissal unless they can reframe their theories around non-preempted grounds [2]. If the Court rules for the plaintiffs, pressure on Bayer to negotiate further global settlements is likely to increase, building on the February agreement already in place [2].